Navigation Links
Lexicon to Present at Morgan Stanley Global Healthcare Conference
Date:9/7/2010

THE WOODLANDS, Texas, Sept. 7 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it will be participating next week in the Morgan Stanley Global Healthcare Conference in New York.  Dr. Arthur T. Sands, president and chief executive officer, will make a presentation on the company on Monday, September 13, 2010 at 10:20 a.m. Eastern Time.

A live audio webcast of the presentation will be accessible through Lexicon's corporate website at www.lexpharma.com. An archived edition of the presentation will be available later that day.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lexicon to Present at Two Major Healthcare Investor Conferences
2. Lexicon Announces Pricing of Common Stock in Public Offering
3. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
4. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
5. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
6. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
7. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
8. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
9. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
10. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
11. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... ear could improve the health of your heart, researchers ... Leeds used a standard TENS machine like those designed ... the tragus, the small raised flap at the front ... canal. , The stimulation changed the influence of the ... signals that can drive failing hearts too hard. , ...
(Date:8/19/2014)... Piscataway, NJ (PRWEB) August 20, 2014 ... engineering and regenerative medicine is an inadequate vascular ... engineered constructs and decellularized tissues is critical for ... Researchers have attempted to mitigate deficiencies in vascularization ... including adding scaffold bioactivity, optimizing scaffold design and ...
(Date:8/19/2014)... A Geisinger researcher on a personal crusade ... for Disease Control and Prevention (CDC) award recognizing his ... Joseph Boscarino , Ph.D. MPH, senior ... of researchers nominated for the Centers for Disease Control ... Data Methods and Study Design. "Hepatitis C ...
(Date:8/19/2014)... Robin Williams’ passing is a sad reminder ... individual. Symptoms range from slowness of voluntary movements ... severe depression. Parkinson’s disease progressively gets worse over ... neurons of the brain. As these patients struggle ... progressively gets worse, they look for options. ...
Breaking Biology Technology:'Tickling' your ear could be good for your heart 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3
... , , BRISBANE, Calif., Sept. 17 ... it will be collaborating with National Jewish Health(R)( )investigators in ... may play a role in idiopathic pulmonary fibrosis (IPF). InterMune ... from patients who participated in the Company,s Phase 3 clinical trials ...
... BETHESDA, Md., Sept. 16 American Capital Ltd. ... 15, it completed the sale of its portfolio company Axygen ... Inc., to Corning Incorporated for approximately $400 million. The ... fee income, from the equity invested by American Capital,s affiliated ...
... SAN MARINO, Calif., Sept. 16 Dr. M. Karen ... (Pink Sheets: VRAL), will address the 11th Annual SoCalBio Investor ... Custom Peptides on Chronic Inflammation," will take place mid-morning on ... The Loews Santa Monica Beach Hotel in Santa Monica, California. ...
Cached Biology Technology:InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis 2InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis 3American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 2American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 3American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 4Viral Genetics' Lead Scientist Dr. M. Karen Newell Will Present at 11th Annual SoCalBio Investor and Partnership Conference 2
(Date:8/21/2014)... pancreatitis involves the pancreas digesting itself resulting in severe ... the UK around 20,000 patients are diagnosed with the ... cure and treatment is restricted to intravenous fluid and ... Faculty of Life Sciences, who led the research, said ... from gall stones and excessive alcohol intake combined with ...
(Date:8/20/2014)... a study of 158 pregnant teenagers in Rochester, NY, ... intentional consumption of ice, cornstarch, vacuum dust, baby powder ... Cornell study. , Moreover, such teens had significantly lower ... eat nonfood substances. , Pregnant teens, regardless of pica, ... lead to iron deficiency and anemia. Low iron in ...
(Date:8/20/2014)... life can persist in a cold, dark world. A ... that examined waters and sediments from a shallow lake ... extreme environment supports microbial ecosystems. , The National ... has implications for life in other extreme environments, both ... are published in the current edition of the science ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Pica in pregnant teens linked to low iron 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... Nature journal Leukemia suggests blocking part of ... leukemia resist treatment can increase the effectiveness of chemotherapy ... Medical Center report that their experimental combination treatment strategy ... was particularly effective at stopping a stubborn leukemia ...
... August 8, 2013 Research and ... addition of the "Fingerprint Biometrics - Global ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,This report ... in US$ Thousands by the following Product ...
... world full of hungry predators, prey animals must be constantly ... challenge when it comes to defending themselves. "One of ... they can,t run away," says John Orrock, a zoology professor ... necessarily hide, so what can you do? Some plants make ...
Cached Biology News:Study suggests way to fight therapy resistant leukemia by blocking DNA repair 2Study suggests way to fight therapy resistant leukemia by blocking DNA repair 3Fingerprint Biometrics: Automated FIS, and Non-AFIS - Global Strategic Business Report - 2013 2Eavesdropping plants prepare to be attacked 2
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... KLH-conjugated, synthetic peptide corresponding ... of mouse p19ARF. The ... acids 62-75. Clone 5-C3-1. ... by immunoblot. Stability ...
Request Info...
Biology Products: